Pomerantz Law Firm Probes Securities Fraud Claims Against Sensus Healthcare, Inc.

Pomerantz Law Firm Investigates Sensus Healthcare, Inc.

Pomerantz LLP, a leading law firm specializing in corporate and securities class actions, has announced an investigation into Sensus Healthcare, Inc. (NASDAQ: SRTS), focusing on potential claims that the company and its executives may have engaged in securities fraud or other unlawful business practices.

On August 7, 2025, Sensus released its financial results for the second quarter, revealing a disappointing GAAP earnings-per-share figure of -$0.06. This outcome fell short of analysts' expectations by $0.09, while the company's revenue of $7.3 million represented a significant decline of 20.7% compared to the same quarter the previous year, missing estimates by $2 million. The decrease was attributed to lower sales to a key customer and was only partially mitigated by an increase in recurring revenue from Fair Deal Agreements.

As a response to these findings, the stock price of Sensus plummeted by $1.89, or 35.32%, closing at $3.46 per share on August 8, 2025. The drastic drop raises significant concerns about the company's operational viability and the potential implications for its shareholders. Investors are encouraged to reach out to Pomerantz LLP for further information about joining the class action lawsuit initiated on behalf of those affected.

The firm, with its rich history of advocating for victims of securities fraud, has established itself as one of the foremost players in this field since its founding over 85 years ago by Abraham L. Pomerantz. The firm has successfully recovered substantial financial awards for its clients, reinforcing its reputation in corporate governance and securities law.

Danielle Peyton, a representative of Pomerantz, is available for inquiries related to this case. Interested parties can contact her at [email protected] or call 646-581-9980 x7980.

This ongoing investigation may serve as a precursor for potential financial restitution for those who invested in Sensus Healthcare and saw their assets diminished due to what could be considered misleading information presented by the company. Investors rely heavily on accurate financial disclosures, and any deviation from these standards can result in severe financial repercussions.

In summary, as Pomerantz steps up its investigation, the ramifications for Sensus Healthcare and its stakeholders will unfold in the coming weeks. Investors should stay informed and consider their options as the legal landscape around this case continues to develop.